Differential Claudin-1 Gene Expression in Neural Crest-Derived Tumors of Common Embryological Origin Abstract #459

Introduction: Pheochromocytoma and paraganglioma are neural crest-derived tumors originating from chromaffin cells, with the former being intra‚Äďadrenal in location, while the latter are extra-adrenal.
Aim(s): To investigate the expression of claudin-1(CLDN1), a tight junction protein marker for metastasis and tumor progression, in neural crest-derived tumors.
Materials and methods: Study comprised of 44 pheochromocytoma, 22 paraganglioma and 11 normal adrenal tissue served as control. RNA extracted from each FFPE tissue was reverse transcribed. Real time PCR experiments were performed to study the gene expression on each sample with GAPDH as control.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Miss Beatrice Philip
Authors: Philip B, Smith R, Lam A
Keywords: Claudin-1

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Housestaff Mary Wong
Authors: Wong M, Huynh C, Kim S, Dhall D, ...
#1683 International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with Yttrium-90 Resin Microspheres
Introduction: Radioembolization (RE) is applied worldwide in patients with liver-dominant metastatic neuroendocrine tumours (mNET). Current literature is of poor quality and based on small heterogeneous populations
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: M.D. Arthur Braat
#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Arthur Braat
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#17 Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls
Introduction: The diagnosis of Zollinger-Ellison syndrome is suspected in patients with symptoms of gastric acid hypersecretion, i.e., peptic ulcer disease, malabsorption or diarrhea, or with elevated fasting serum gastrin levels. However, symptoms can be masked by the use of proton pump inhibitors and fasting serum gastrin values are not always conclusive. Therefore, the secretin stimulation test is advocated as the principal diagnostic tool to identify the Zollinger-Ellison syndrome.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Patricia Kuiper